David Happel News Today

Platinum Investment Management Ltd. lowered its position in Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) by 70.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 111,752 shares of the company’s stock after selling 272,161 shares during the period. Platinum Investment Management Ltd. owned 0.52% of Sagimet Biosciences […]

HC Wainwright reaffirmed their buy rating on shares of Sagimet Biosciences (NASDAQ:SGMT – Free Report) in a research report released on Friday morning, Benzinga reports. The brokerage currently has a $32.00 target price on the stock. Several other brokerages also recently issued reports on SGMT. Leerink Partnrs reissued an outperform rating on shares of Sagimet […]

JMP Securities reissued their market outperform rating on shares of Sagimet Biosciences (NASDAQ:SGMT – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $48.00 target price on the stock. Several other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a buy rating […]

Sagimet Biosciences Inc. (NASDAQ:SGMT – Get Free Report) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued a report on the stock […]

The Liver Meeting® 2023 showcasing the beneficial shift in lipid profile in denifanstat-treated patients End-of-Phase 2 meeting with U.S. Food and Drug Administration expected in first half of...

Denifanstat was well-tolerated and met primary endpoint in planned interim readout with 67% of treated patients achieving ≥30% reductions in liver fat at week 26 compared to 18% placebo (p<0.001)

Biotech drug developer Sagimet Biosciences is taking another shot at going public, according to a filing with the SEC late Friday.